406 related articles for article (PubMed ID: 27613250)
1. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
[TBL] [Abstract][Full Text] [Related]
3. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
[No Abstract] [Full Text] [Related]
4. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
[TBL] [Abstract][Full Text] [Related]
5. A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.
Santamaria M; Neth O; Douglass JA; Krivan G; Kobbe R; Bernatowska E; Grigoriadou S; Bethune C; Chandra A; Horneff G; Borte M; Sonnenschein A; Kralickova P; Ramón SS; Langguth D; Gonzalez-Granado LI; Alsina L; Querolt M; Griffin R; Hames C; Mondou E; Price J; Sanz A; Lin J
J Clin Immunol; 2022 Apr; 42(3):500-511. PubMed ID: 34973143
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
Front Immunol; 2019; 10():40. PubMed ID: 30778345
[No Abstract] [Full Text] [Related]
7. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
McCormack PL
BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age.
Patel NC; Gallagher JL; Ochs HD; Atkinson TP; Wahlstrom J; Dorsey M; Bonilla FA; Heimall J; Kobrynski L; Morris D; Haddad E
J Clin Immunol; 2015 Aug; 35(6):558-65. PubMed ID: 26336818
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.
Borte M; Bernatowska E; Ochs HD; Roifman CM;
Clin Exp Immunol; 2011 Jun; 164(3):357-64. PubMed ID: 21413943
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency.
Church JA; Leibl H; Stein MR; Melamed IR; Rubinstein A; Schneider LC; Wasserman RL; Pavlova BG; Birthistle K; Mancini M; Fritsch S; Patrone L; Moore-Perry K; Ehrlich HJ;
J Clin Immunol; 2006 Jul; 26(4):388-95. PubMed ID: 16705486
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.
Melamed I; Testori A; Spirer Z
Int Rev Immunol; 2012 Dec; 31(6):451-61. PubMed ID: 23215767
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
Shapiro RS
Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
[TBL] [Abstract][Full Text] [Related]
20. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]